The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT07761728
Status
Recruiting
Apply to this trial

Conditions

  • Coronary Artery Disease
  • Coronary Microvascular Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study seeks to evaluate if the diagnostic performance of 18F-flurpiridaz positron emission tomography (PET) myocardial perfusion imaging (MPI), given the radiotracer's properties, is non-inferior to the currently most widely utilized PET MPI radiopharmaceutical, 82Rb-chloride.

Key Dates

First listed
Aug 12, 2026
Start date
Aug 13, 2025
Status verified
Aug 2026
Primary completion
Dec 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Patients Undergoing Myocardial Perfusion Imaging
    Patients scheduled for a clinically indicated myocardial perfusion imaging study with 82Rb-chloride who subsequently undergo MPI with 18F-flurpiridaz as well as a CT coronary angiogram.

Primary Outcome Measure

18F-Flurpiridaz Diagnostic Performance [ Time Frame: From enrollment to completion of CT coronary angiography, an average of 10 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
West Los Angeles Veterans Affairs Medical CenterLos AngelesCalifornia90073
Rene R Packard, MD, PhD
[email protected]
310-825-4467
Gholam R Berenji, MD
Rene R Packard, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
West Los Angeles Veterans Affairs Medical Center· Los Angeles, CA

Related Studies